Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (DE:4KB)
FRANKFURT:4KB
Krystal Biotech (4KB) Stock Price & Analysis
0 Followers
4KB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€75.00 - €167.80
Previous Close€149.2
Volume0.00
Average Volume (3M)40.00
Market Cap
€4.23B
Enterprise Value€3.71B
Total Cash (Recent Filing)$562.07M
Total Debt (Recent Filing)$8.32M
Price to Earnings (P/E)N/A
Beta0.30
Next Earnings
May 06, 2024EPS Estimate
€0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,292,616
10 Day Avg. Volume1
30 Day Avg. Volume40
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.85
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-157.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue431.93
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-342.58
Forecast
1Y Price Target
€179.62Price Target Upside20.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Krystal Biotech News
Bulls Say, Bears Say
Bulls Say
Drug Development & ApprovalThe FDA recently cleared an amendment to the KB707 IND to evaluate inhaled KB707 to treat tumors in patient's lungs, representing a pioneering therapeutic approach in oncology.
Financial PerformanceKrystal's EPS for 4Q23 and FY23 surpassed analyst and consensus estimates, showcasing a stronger than expected financial performance.
Market AdoptionWith Vyjuvek's FDA approval and the addressing of patient scheduling issues, the drug is set for increased adoption, potentially leading to an upside in sales.
Bears Say
EarningsInvestor skepticism following the 3Q sales miss and management's cautioning of seasonality in 4Q.
LeadershipConcerns for the commercial execution in the absence of a Chief Commercial Officer.
Sales ForecastManagement cautioned about potential seasonality impacts on fourth-quarter sales, contributing to investor skepticism.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
3.30% Other Institutional Investors
96.70% Public Companies and
Individual Investors
4KB FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was €75.00 and its highest was €167.80 in the past 12 months.
What is Krystal Biotech’s market cap?
Currently, no data Available
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is May 06, 2024 which is today.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Feb 26, 2024. The company reported €0.28 earnings per share for the quarter, beating the consensus estimate of -€0.287 by €0.567.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is €0.25.
How many shares outstanding does Krystal Biotech have?
Currently, no data Available
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of €0.28 in its last earnings report, beating expectations of -€0.287. Following the earnings report the stock price went down -0.971%.
Which hedge fund is a major shareholder of Krystal Biotech?
Among the largest hedge funds holding Krystal Biotech’s share is Woodline Partners LP. It holds Krystal Biotech’s shares valued at 60M.
---
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€179.62 (20.39% Upside)
€179.62 (20.39% Upside)
Blogger Sentiment
Bullish
DE:4KB Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.99%
12-Months-Change
Fundamentals
Return on Equity
1.68%
Trailing 12-Months
Asset Growth
46.54%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
---
4KB Company Deck
---
4KB Earnings Call
Q4 2024
0:00 / 0:00
---
4KB Stock 12 Months Forecast
Average Price Target
€179.62
▲(20.39% Upside)
Technical Analysis
Best Analysts Covering 4KB
1 Year
1 Year Success Rate
13/13 ratings generated profit
1 Year Average Return
+52.26%
reiterated a buy rating 6 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +52.26% per trade.
---